New for 2026
Medicare now covers weight-loss GLP-1s. Here’s the $50-a-month fine print.
Short answer: yes, as of July 1, 2026. Through a temporary federal program called the Medicare GLP-1 Bridge, eligible Medicare drug-plan enrollees can get certain weight-loss GLP-1 medications for a flat $50 monthly copay through December 31, 2027. It works differently from normal drug coverage in ways that affect your budget, your pharmacy visit, and your plan choice. All of it below.
Key takeaways
- The Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027 and charges a flat $50 per monthly supply in every coverage phase.
- Covered drugs: Wegovy (injection and tablets), Zepbound in the KwikPen formulation only, and Foundayo in all formulations.
- The Bridge operates outside Part D: the $50 does not count toward your deductible or the $2,100 annual out-of-pocket drug cap.
- Your plan doesn’t need to opt in; a single CMS central processor handles prior authorization and claims nationwide.
- Ozempic is still covered only under regular Part D for diabetes, not through the Bridge for weight loss.
Why this is new
Since Part D launched in 2006, federal law has prohibited Medicare drug plans from covering medications prescribed for weight loss. The same molecule could be covered for one diagnosis and excluded for another: semaglutide as Ozempic for type 2 diabetes, covered; semaglutide as Wegovy for obesity, excluded. Changing that law requires Congress.
CMS found a lane it does control: demonstration authority. On December 23, 2025 it announced a temporary program, now called the Medicare GLP-1 Bridge, that pays for specific weight-loss GLP-1s outside the Part D benefit entirely. It launched July 1, 2026. A planned successor program (BALANCE) was supposed to take over in Part D in January 2027, but CMS delayed that piece indefinitely in May 2026 and extended the Bridge through December 31, 2027.
The rules, decoded
- Dates: July 1, 2026 through December 31, 2027.
- Cost to you: a flat $50 per monthly supply, regardless of coverage phase, income, or plan.
- Who’s eligible: you must be enrolled in a stand-alone Part D plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD), and the drug must be prescribed to reduce excess body weight and maintain that reduction. Full criteria are on the official CMS program page.
- Plumbing: your plan does not opt in and does not process the claim. A single CMS central processor handles prior authorization, claims, and pharmacy payment nationwide. That means the answer at the counter shouldn’t depend on which insurer’s card is in your wallet.
Which drugs, exactly
| Drug | Formulations covered | Notes |
|---|---|---|
| Wegovy (semaglutide) | Injection and tablets | Both forms eligible |
| Zepbound (tirzepatide) | KwikPen only | Single-dose vials and single-dose pens are NOT eligible |
| Foundayo | All formulations | Added April 6, 2026 after FDA approval |
| Ozempic (semaglutide) | Not in the Bridge | Covered under regular Part D for diabetes only |
Eligible drug list per CMS, updated April 6, 2026. Formulation details matter at the pharmacy: a Zepbound vial prescription will not run through the Bridge.
How to actually get it, step by step
- Confirm your drug coverage. You need a PDP or MA-PD. If you’re on Original Medicare with no drug plan, enrolling in one is the prerequisite.
- Talk to your prescriber about the covered list. The prescription needs to be for an eligible drug, in an eligible formulation, for weight reduction. If you’re on a Zepbound vial today, that means a switch to the KwikPen.
- Prior authorization goes through the central processor. Your doctor submits it there, not to your insurer. Ask the office to note it’s a Medicare GLP-1 Bridge claim; the program is new enough that not every front desk knows the routing yet.
- Fill at the pharmacy for $50. If the counter quotes you anything else, the claim likely ran through your Part D plan (where weight-loss GLP-1s remain excluded) instead of the Bridge. Ask them to reprocess it through the Bridge before paying out of pocket.
What the $50 doesn’t count toward
The catch most coverage skips: because the Bridge sits outside Part D, your $50 payments do not count toward your Part D deductible and do not count toward the $2,100 annual out-of-pocket drug cap. Budget it as a separate line: $600 a year if you fill all twelve months, on top of whatever your regular drugs cost.
It also means the Bridge can’t be gamed the other direction: hitting your $2,100 cap on other drugs doesn’t make Bridge fills free. The two systems don’t talk to each other financially.
Does this change the Advantage vs. Original Medicare decision?
Barely, and that’s the useful news. Because the program is federal and centrally processed, it works identically whether your drug coverage is a stand-alone Part D plan next to Original Medicare and Medigap, or built into a Medicare Advantage plan. It shouldn’t push you between paths. Where it does belong is in your total monthly math: if a GLP-1 is part of your treatment plan, a predictable $50 changes your budget on either path, and it stacks on top of the roughly $340 to $460 all-in monthly cost of the Original Medicare route or the $203-and-up cost of the Advantage route.
What happens after 2027
Nobody can promise. The Bridge was built as a ramp to a bigger program whose Part D piece is now delayed indefinitely. Congress could change the underlying weight-loss exclusion, extend the demonstration again, or let it lapse. The planning posture that fits the facts: treat the Bridge as real money-saving access today, keep receipts and documentation of medical necessity in case rules tighten, and don’t anchor a decade of financial planning to a program with an expiration date printed on it.
Questions people also ask
Does Medicare cover Ozempic, Wegovy, or Zepbound for weight loss in 2026?
How much do GLP-1 drugs cost under the Medicare Bridge program?
Do I need a special plan to use the Medicare GLP-1 Bridge?
Why was my Zepbound prescription rejected under the Bridge?
Will Medicare still cover weight-loss drugs after 2027?
Sources for this article
- CMS.govMedicare GLP-1 Bridge: the official program page, eligible drugs, formulations, and dates.
- CMS.govCMS press release, May 6, 2026: the $50 monthly amount and the July 1, 2026 launch.
- Medicare.govMedicare drug coverage costs: how the normal Part D phases and the $2,100 cap work, which the Bridge sits outside of.
Figures checked against these sources in July 2026. We update within weeks when CMS publishes new amounts.